Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD)

Market Closed
24 Feb, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
147. 64
-2.19
-1.46%
$
187.84B Market Cap
17.2 P/E Ratio
3.08% Div Yield
8,137,554 Volume
6.22 Eps
$ 149.83
Previous Close
Day Range
147.06 150.08
Year Range
93.37 157.29
Want to track GILD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
GILD earnings report is expected in 56 days (22 Apr 2026)
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 6 months ago
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.

Zacks | 7 months ago
Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 7 months ago
EU regulator backs Gilead's twice-yearly injection for HIV prevention

EU regulator backs Gilead's twice-yearly injection for HIV prevention

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said on Friday.

Reuters | 7 months ago
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its last close.

Zacks | 7 months ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks | 7 months ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 7 months ago
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

Here's Why Gilead Sciences (GILD) Fell More Than Broader Market

Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.

Zacks | 7 months ago
WHO recommends Gilead's twice-yearly injection for HIV prevention

WHO recommends Gilead's twice-yearly injection for HIV prevention

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Reuters | 7 months ago
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 7 months ago
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.

Zacks | 7 months ago
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 7 months ago
Loading...
Load More